Syndexa gets $15M for metabolic disease work

With help from technology entrepreneur Dr. Yalcin Ayasli, Cambridge, MA-based Syndexa Pharmaceuticals has garnered $15 million in a second round of financing. The company previously raised about $4 million in a seed round and is developing drugs for chronic inflammation, neurodegenerative disorders and obesity-related conditions--including type 2 diabetes. The start-up was founded by Gokhan Hotamisligil using technology he developed at the Harvard School of Public Health.

"This new influx of capital reflects the enormous promise of Syndexa's drug targets, Endoplasmic Reticulum and c-jun N-terminal kinase. Attracting additional capital at an increased valuation is a testament to the robust product potential of our innovative drug discovery approach and the strength of our team," said Teo Uysal, CEO and co-founder of Syndexa. "We are thrilled to partner with our new investor Dr. Ayasli whose experience will bring a new dimension to the Syndexa team as we move forward."

- read Syndexa's release for more on the financing

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.